Unknown

Dataset Information

0

Inclusion of Flagellin during Vaccination against Influenza Enhances Recall Responses in Nonhuman Primate Neonates.


ABSTRACT: Influenza virus can cause life-threatening infections in neonates and young infants. Although vaccination is a major countermeasure against influenza, current vaccines are not approved for use in infants less than 6 months of age, in part due to the weak immune response following vaccination. Thus, there is a strong need to develop new vaccines with improved efficacy for this vulnerable population. To address this issue, we established a neonatal African green monkey (AGM) nonhuman primate model that could be used to identify effective influenza vaccine approaches for use in young infants. We assessed the ability of flagellin, a Toll-like receptor 5 (TLR5) agonist, to serve as an effective adjuvant in this at-risk population. Four- to 6-day-old AGMs were primed and boosted with inactivated PR8 influenza virus (IPR8) adjuvanted with either wild-type flagellin or inactive flagellin with a mutation at position 229 (m229), the latter of which is incapable of signaling through TLR5. Increased IgG responses were observed following a boost, as well as at early times after challenge, in infants vaccinated with flagellin-adjuvanted IPR8. Inclusion of flagellin during vaccination also resulted in a significantly increased number of influenza virus-specific T cells following challenge compared to the number in infants vaccinated with the m229 adjuvant. Finally, following challenge infants vaccinated with IPR8 plus flagellin exhibited a reduced pathology in the lungs compared to that in infants that received IPR8 plus m229. This study provides the first evidence of flagellin-mediated enhancement of vaccine responses in nonhuman primate neonates.Young infants are particularly susceptible to severe disease as a result of influenza virus infection. Compounding this is the lack of effective vaccines for use in this vulnerable population. Here we describe a vaccine approach that results in improved immune responses and protection in young infants. Incorporation of flagellin during vaccination resulted in increased antibody and T cell responses together with reduced disease following virus infection. These results suggest that flagellin may serve as an effective adjuvant for vaccines targeted to this vulnerable population.

SUBMITTER: Kim JR 

PROVIDER: S-EPMC4473543 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inclusion of Flagellin during Vaccination against Influenza Enhances Recall Responses in Nonhuman Primate Neonates.

Kim Jong R JR   Holbrook Beth C BC   Hayward Sarah L SL   Blevins Lance K LK   Jorgensen Matthew J MJ   Kock Nancy D ND   De Paris Kristina K   D'Agostino Ralph B RB   Aycock S Tyler ST   Mizel Steven B SB   Parks Griffith D GD   Alexander-Miller Martha A MA  

Journal of virology 20150506 14


<h4>Unlabelled</h4>Influenza virus can cause life-threatening infections in neonates and young infants. Although vaccination is a major countermeasure against influenza, current vaccines are not approved for use in infants less than 6 months of age, in part due to the weak immune response following vaccination. Thus, there is a strong need to develop new vaccines with improved efficacy for this vulnerable population. To address this issue, we established a neonatal African green monkey (AGM) non  ...[more]

Similar Datasets

| S-EPMC8341655 | biostudies-literature
| S-EPMC3828296 | biostudies-literature
| S-EPMC4319312 | biostudies-literature
| S-EPMC2583664 | biostudies-literature
| S-EPMC5801566 | biostudies-literature
| S-EPMC6814850 | biostudies-literature
| S-EPMC8416058 | biostudies-literature
| S-EPMC7042048 | biostudies-literature
| S-EPMC8312020 | biostudies-literature
| S-EPMC304106 | biostudies-other